Loading clinical trials...

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities

NCT05822830•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a body mass index (BMI) of ≥30 kilogram per square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
•Have a history of at least 1 unsuccessful dietary effort to lose body weight

Exclusion Criteria

•Diabetes mellitus
•Change in body weight greater than 5 kg within 3 months prior to starting study
•Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
•History of pancreatitis
•Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
•History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years

Locations (32)

Cahaba Research

Birmingham, Alabama, United States

Cahaba Research - Pelham

Pelham, Alabama, United States

Southern California Dermatology, Inc.

Santa Ana, California, United States

Encompass Clinical Research

Spring Valley, California, United States

University Clinical Investigators, Inc.

Tustin, California, United States

Velocity Clinical Research, Hallandale Beach

Hallandale, Florida, United States

New Horizon Research Center

Miami, Florida, United States

ForCare Clinical Research

Tampa, Florida, United States

Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, United States

Rocky Mountain Clinical Research

Idaho Falls, Idaho, United States

Key Dates

Start Date

April 21, 2023

Primary Completion Date

November 13, 2024

Completion Date

November 13, 2024

Last Updated

November 26, 2025

Enrollment

751

ACTUAL participants

Conditions

ObesityOverweight

Interventions

Tirzepatide

DRUG

Semaglutide

DRUG

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss